Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

NCT04460430 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT04460430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04460430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 2
Overall status
Terminated
Start date
July 23, 2020
Completion date
November 29, 2021
Enrollment
12 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer